Xcout IntelMosaic ImmunoEngineering Inc. competitors & alternatives
The 12 closest competitors and alternatives to Mosaic ImmunoEngineering Inc. among biotech companies — ranked by similarity to what Mosaic ImmunoEngineering Inc. actually does, not by market-cap band.
Subscribe to see Mosaic ImmunoEngineering Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Mosaic ImmunoEngineering Inc. at a glance
Mosaic ImmunoEngineering Inc. is a biotech company headquartered in Huntington Beach, United States. It is publicly listed (CPMV) with a market capitalisation of $441,770. Xcout tracks 23 named people at Mosaic ImmunoEngineering Inc., including Steven W. King (Chairman of the Board, President, CFO & CEO).
Mosaic ImmunoEngineering Inc. leadership
- Steven W. KingChairman of the Board, President, CFO & CEO
- Steven KingPresident and Chief Executive Officer, Director
- Paul LytleEVP, Chief Financial Officer, Director
- Lisa SteppVP, Patient and Government Engagement
- Shelley FusseyVP, Intellectual Property
- Cyril EmpigHead of Vaccine Development
17 more named people on record for Mosaic ImmunoEngineering Inc., with roles, board committees and tenure — see the full roster →
Top 12 Mosaic ImmunoEngineering Inc. competitors
Ranked by semantic similarity — how close each company is to Mosaic ImmunoEngineering Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Monocacy Therapeutics Inc. develops artificial intelligence-guided, first-in-class immune medicines designed to restore optimal immune function and patient health. The company utilizes a full-stack, AI-powered immunology platform to discover and develop next-generation immunotherapies for patients.
Similar biotech company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Biotechnology
Mosaic Biosciences, Inc. is a biotechnology company based in Boulder, Colorado. The firm operates research and corporate facilities to support scientific discovery and development.
Biotechnology
Hookipa Pharma Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines based on arenavirus vectors, designed to stimulate targeted T-cell and antibody responses. Its programs have focused on cancer and infectious diseases, serving patients through potential therapeutic and preventive treatments.
Biotechnology
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
Biotechnology
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Biotechnology
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Biotechnology
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Biotechnology
Irazu Oncology, LLC is a biotechnology company that develops cancer immunotherapies utilizing bacterial outer membrane vesicles. The company creates off-the-shelf treatments designed to activate anti-tumor immune responses through a scalable manufacturing process, aiming to provide more accessible and affordable therapeutic options for cancer patients.
Biotechnology
ImmunoScape is a biotechnology company developing combination cancer therapies, specifically utilizing a novel seed-and-boost approach designed to deliver anti-tumor efficacy at a lower cost. The company serves the biopharmaceutical and oncology healthcare sectors.
Biotechnology
ME Therapeutics Holdings Inc. is a clinical-stage biotechnology company that discovers and develops immuno-oncology therapeutics designed to reprogram immune cells in vivo. Its pipeline aims to activate the body's immune system to recognize and fight cancer cells.
Similar biotech company
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Mosaic ImmunoEngineering Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Mosaic ImmunoEngineering Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →